{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:23:11Z","timestamp":1790868191829,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T00:00:00Z","timestamp":1256601600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10549-009-0592-x","type":"journal-article","created":{"date-parts":[[2009,10,26]],"date-time":"2009-10-26T05:19:09Z","timestamp":1256534349000},"page":"685-697","source":"Crossref","is-referenced-by-count":71,"title":["EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance"],"prefix":"10.1007","volume":"122","author":[{"given":"Rajiv","family":"Dua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phets","family":"Nhonthachit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elicia","family":"Penuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,27]]},"reference":[{"key":"592_CR1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","volume":"421","author":"HS Cho","year":"2003","unstructured":"Cho HS, Masonn K, Ramyar KX et al (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756\u2013760","journal-title":"Nature"},{"key":"592_CR2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX (2001) Untangling the ERBB signalling network. Nat Mol Cell Biol 2:127\u2013137","journal-title":"Nat Mol Cell Biol"},{"key":"592_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"592_CR4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"592_CR5","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"592_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117\u2013127","journal-title":"Cancer Cell"},{"key":"592_CR7","doi-asserted-by":"crossref","unstructured":"Ginestier C, Adelaide J, Gonclaves A, et al (2007) ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26:7163\u20137169","DOI":"10.1038\/sj.onc.1210528"},{"key":"592_CR8","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-07-5962","volume":"68","author":"DL Shattuck","year":"2008","unstructured":"Shattuck DL, Miller JK, Carraway KL et al (2008) Met receptor contributes to trastuzumab resistance of Her-2 overexpressing breast cancer cells. Cancer Res 68:1471\u20131477","journal-title":"Cancer Res"},{"key":"592_CR9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/0008-5472.CAN-04-3841","volume":"65","author":"R Nahta","year":"2005","unstructured":"Nahta R, Yuan LX, Zhang B et al (2005) Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:1118\u20131128","journal-title":"Cancer Res"},{"key":"592_CR10","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","volume":"93","author":"Y Lu","year":"2001","unstructured":"Lu Y, Zi X, Zhao Y et al (2001) Insulin-like growth factor-I receptor signaling and resistance to Trastuzuman (Herceptin). J Natl Cancer Inst 93:1852\u20131857","journal-title":"J Natl Cancer Inst"},{"key":"592_CR11","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1158\/1078-0432.CCR-07-0701","volume":"13","author":"CA Ritter","year":"2007","unstructured":"Ritter CA, Marianela PT, Rinehart C et al (2007) Human breast cancer cells selected for resistance in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909\u20134919","journal-title":"Clin Cancer Res"},{"key":"592_CR12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ncponc1179","volume":"5","author":"A Prat","year":"2008","unstructured":"Prat A, Baselga J (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5:531\u2013542","journal-title":"Nat Clin Pract Oncol"},{"issue":"suppl 6","key":"592_CR13","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0959-8049(01)81186-2","volume":"37","author":"RD Mass","year":"2001","unstructured":"Mass RD, Vogel C, Murphy M et al (2001) Relationship of estrogen receptor (ER) status to clinical benefit in clinical trials of Herceptin. Eur J Cancer 37(suppl 6):S190","journal-title":"Eur J Cancer"},{"key":"592_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3816\/CBC.2005.n.027","volume":"6","author":"A Brufsky","year":"2005","unstructured":"Brufsky A, Lembersky B, Schiffman K et al (2005) Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 6:247\u2013252","journal-title":"Clin Breast Cancer"},{"key":"592_CR15","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/0008-5472.CAN-08-0857","volume":"69","author":"G Sabnis","year":"2009","unstructured":"Sabnis G, Schayowitz A, Goloubeva O et al (2009) Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 69:1416\u20131428","journal-title":"Cancer Res"},{"key":"592_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/PDM.0b013e31818cbdb2","volume":"18","author":"Y Shi","year":"2009","unstructured":"Shi Y, Huang W, Tan Y et al (2009) A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol 18:11\u201321","journal-title":"Diagn Mol Pathol"},{"key":"592_CR17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/PDM.0b013e31818ebc69","volume":"18","author":"C Desmedt","year":"2009","unstructured":"Desmedt C, Sperinde J, Piette F et al (2009) Quantitation of HER2 expression or HER2: HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol 18:22\u201329","journal-title":"Diagn Mol Pathol"},{"key":"592_CR18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","volume":"318","author":"JM Stommel","year":"2007","unstructured":"Stommel JM, Kimmelman AC, Ying H et al (2007) Coactivation of receptor tyrosine kinase affects the response of tumor cells to targeted therapies. Science 318:287\u2013290","journal-title":"Science"},{"key":"592_CR19","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","volume":"22","author":"MD Pegram","year":"1998","unstructured":"Pegram MD, Lipton A, Hayes DF et al (1998) Phase II recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 22:2659\u20132671","journal-title":"J Clin Oncol"},{"key":"592_CR20","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER-2 positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"key":"592_CR21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepard","year":"2005","unstructured":"Shepard FA, Periera JR, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"592_CR22","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"key":"592_CR23","doi-asserted-by":"crossref","unstructured":"Juntilla TT, Akita RW, Parsons K, et al (2009) Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429\u2013440","DOI":"10.1016\/j.ccr.2009.03.020"},{"key":"592_CR24","first-page":"60","volume":"26","author":"MX Sliwkowski","year":"1999","unstructured":"Sliwkowski MX, Lofgren JA, Lewis GD et al (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin). Sem Oncol 26:60\u201370","journal-title":"Sem Oncol"},{"key":"592_CR25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/MCB.11.2.979","volume":"11","author":"R Kumar","year":"1991","unstructured":"Kumar R, Shepard HM, Medelson J (1991) Regulation of phosphorylation of the c-erbB-2\/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol 11:979\u2013986","journal-title":"Mol Cell Biol"},{"key":"592_CR26","first-page":"3207","volume":"121","author":"R Tao","year":"2009","unstructured":"Tao R, Maruyama I (2009) All EGF (ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Biol 121:3207\u20133217","journal-title":"J Cell Biol"},{"key":"592_CR27","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1091\/mbc.01-08-0411","volume":"13","author":"X Yu","year":"2002","unstructured":"Yu X, Sharma KD, Takahasi T et al (2002) Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Mol Cell Biol 13:2547\u20132557","journal-title":"Mol Cell Biol"},{"key":"592_CR28","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-08-1056","volume":"69","author":"M Narayan","year":"2009","unstructured":"Narayan M, Wilken JA, Harris LN et al (2009) Trastuzumab-induced HER reprogramming in \u201cresistant\u201d breast carcinoma cells. Cancer Res 69:2191\u20132194","journal-title":"Cancer Res"},{"key":"592_CR29","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1535-7163.MCT-08-0168","volume":"7","author":"D Zhang","year":"2008","unstructured":"Zhang D, Pal A, Bornmann WG et al (2008) Activity of lapatinib is independent of EGFR expression level in HER2-overexpressin breast cancer cells. Mol Cancer Ther 7:1846\u20131850","journal-title":"Mol Cancer Ther"},{"key":"592_CR30","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1158\/1078-0432.CCR-09-0872","volume":"15","author":"BN Rexer","year":"2009","unstructured":"Rexer BN, Ghosh R, Arteaga CL (2009) Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin Cancer Res 15:4518\u20134520","journal-title":"Clin Cancer Res"},{"key":"592_CR31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/onc.2008.432","volume":"28","author":"M Scaltriti","year":"2008","unstructured":"Scaltriti M, Verma C, Guzman M et al (2008) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:803\u2013814","journal-title":"Oncogene"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-009-0592-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0592-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:32:22Z","timestamp":1559233942000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-009-0592-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,27]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1007\/s10549-009-0592-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,27]]}}}